Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2017 February;65(1) > Minerva Cardioangiologica 2017 February;65(1):68-73

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

REVIEW  


Minerva Cardioangiologica 2017 February;65(1):68-73

DOI: 10.23736/S0026-4725.16.04240-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

The year since the guidelines: a concise update on recent advances in pulmonary hypertension

Abhishek MISHRA, Maninder SINGH, Edo KALUSKI

Division of Cardiology, Guthrie Clinic, Robert Packer Hospital, Sayre, PA, USA


PDF  


Since the updated pulmonary hypertension (PH) guidelines published in 2015, two major landmark trials have provided additional insight regarding therapeutic algorithms of PH. In this review, we concisely summarized the key findings of peer‑reviewed studies published in the last one year in the field of PH. These studies have enhanced our therapeutic abilities by introducing a new potent agent, selexipag, and by demonstrating the advantage of upfront combination therapy (endothelin receptor antagonist and phosphodiesterase‑5 inhibitor) versus single agent therapy in group 1 PH. The addition of these therapeutic options resulted in mild improvement in certain clinical endpoints. Disappointingly, the improvement in clinical and hemodynamic endpoints was modest, not “across the board” and did not result in a measurable mortality reduction. Similarly, the role of agents traditionally used predominantly for primary PH or PH associated with connective tissues disease were tested in subjects with predominantly left heart failure. The progress in diagnostic modalities and strategies such as evaluation and validation of newer biomarkers, impact of borderline elevated pulmonary pressure and the role of various imaging modalities is briefly discussed but these investigations bears no groundbreaking amendments in current diagnostic algorithms.


KEY WORDS: Pulmonary hypertension - Therapeutics - Selexipag

inizio pagina

Publication History

Issue published online: November 30, 2016
Article first published online: September 22, 2016

Per citare questo articolo

Mishra A, Singh M, Kaluski E. The year since the guidelines: a concise update on recent advances in pulmonary hypertension. Minerva Cardioangiol 2017;65:68-73. DOI: 10.23736/S0026-4725.16.04240-7

Corresponding author e-mail

ekaluski@gmail.com